The market is segmented based on
Marché mondial de la colite ulcéreuse, par type (rectite ulcéreuse, rectosigmoïdite, colite gauche, pan-colite ou colite universelle et colite fulminante), type de médicament (anti-inflammatoires, salicylates aminés, corticostéroïdes, produits biologiques anti-TNF, immunosuppresseurs , inhibiteurs de la calcineurine et autres), type de molécule (petites molécules et produits biologiques), voie d'administration (injectable et orale), canal de distribution (pharmacies hospitalières, pharmacies de détail, pharmacies et autres) - Tendances et prévisions de l'industrie jusqu'en 2030.
.
The Global Ulcerative Colitis Market size was valued at USD 7321.78 USD Million in 2023.
The Global Ulcerative Colitis Market is projected to grow at a CAGR of 5.7% during the forecast period of 2024 to 2030.
The major players operating in the market include Johnson &, Johnson ServicesInc. , Bayer AG , AbbVie Inc. , Merck &, Co.Inc. , Takeda Pharmaceutical Company Limited , GlaxoSmithKline plc. , F. Hoffmann-La Roche Ltd , Pfizer Inc. , Abbott , Astrazeneca , Sanofi , Allergan , CELGENE CORPORATION , Bristol-Myers Squibb Company , InDex Pharmaceuticals Holding AB .
Corporate Email ID Only (Avoid Using Generic mail ID such as Gmail)
Consent Preferences
We use cookies to improve your experience We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies. Cookie Notice.
The data presented is for visualization purposes only and may not reflect actual results.